+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

A comparison study of multiple measures of adherence to HIV protease inhibitors

Annals of Internal Medicine 134(10): 968-977

A comparison study of multiple measures of adherence to HIV protease inhibitors

A longitudinal cohort study was conducted to examine the relationship among a composite score of adherence, the 3 primary measures of adherence, and HIV virologic response in 108 HIV-infected adults receiving protease inhibitors or non-nucleoside reverse transcriptase inhibitors, monitored for 666 monthly intervals. Medication Event Monitoring System (MEMS), pill count, and interview combined into a composite adherence score (CAS), and HIV viral load were measured.

Accession: 003342170

PMID: 11352698

DOI: 10.7326/0003-4819-134-10-200105150-00011

Related references

Cassidy, C.M.; Rabinovitch, M.; Schmitz, N.; Joober, R.; Malla, A., 2010: A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis. This study evaluates how much agreement there is between subjective reports of adherence to antipsychotic medication and objective or derived measures of adherence in first-episode psychosis (FEP) and asks if any adherence measure could approximat...

Yasuda, J.; Miller, C.; Little, S.; Currier, J.; Forthal, D.; Kemper, C.; Beall, G.; Capparelli, E.; Mccutchan, J.; Haubrich, R.; Cctg, 2002: Correlation between repeated measures of plasma concentrations of protease inhibitors, medication adherence, and virologic outcome in HIV-infected patients. Background: There is no "gold standard" for measuring adherence. The objective of the analysis was to assess the independent predictive value of protease inhibitor concentrations (PICs) as a supplement to self-reported (SR) adherence. Me...

Lapins, M.; Wikberg, J.E.S., 2009: Proteochemometric modeling of drug resistance over the mutational space for multiple HIV protease variants and multiple protease inhibitors. The main therapeutic targets in HIV are its protease and reverse transcriptase. A major problem in treatment of HIV is the ability of the virus to develop drug resistance by accumulating mutations in its targets. Acquiring detailed understanding o...

Frey C.L.; Barone J.M.; Dreyer G.; Koltin Y.; Petteway S.R.Jr; Drutz D.J., 1990: Synthetic protease inhibitors inhibit candida albicans extracellular acid protease activity and adherence to endothelial cells. Abstracts of the Annual Meeting of the American Society for Microbiology 90: 425

Lazzarini, L.; Lanzafame, M.; Polo, A.; Vento, S.; Concia, E., 2000: Adherence to treatment with protease inhibitors and therapeutic outcome in an unselected cohort of HIV-infected patients: A retrospective study. Objectives: A retrospective study was carried out to assess the relationship between medication adherence to protease inhibitors and therapeutic outcome in an unselected cohort of HIV infected patients. Methods: 173 patients, undergoing a triple a...

Hilgeroth, A.; Fleischer, R.; Wiese, M.; Heinemann, F.W., 1999: Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cage dimeric N-benzyl 4-(4-methoxyphenyl)-1,4-dihydropyridine as representative of a novel class of HIV-1 protease inhibitors: a molecular modeling study. The functional groups of cage dimeric N-alkyl substituted 3,5-bis(hydroxymethyl)-4-(4-methoxyphenyl)-1,4-dihydropyridines are similar to those of cyclic and azacyclic ureas that are potent inhibitors of HIV-1 protease of the dihydroxyethylene- and...

Gardner, E.M.; Melendez, A.G.; Astiz, M.; Bray, K., 2014: Adherence and preexisting major protease inhibitor resistance mutations are associated with virologic failure of a dual-class antiretroviral regimen with inhibitors of HIV-1 viral protease and integrase. Novel treatment strategies are needed for treatment-experienced HIV-infected individuals. We retrospectively evaluated virologic outcomes on a dual-class, protease inhibitor (PI) plus raltegravir, antiretroviral (ARV) regimen. Virologic success wa...

Oyugi, J.H.; Byakika-Tusiime, J.; Charlebois, E.D.; Kityo, C.; Mugerwa, R.; Mugyenyi, P.; Bangsberg, D.R., 2004: Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. Background: There are no validated measures of adherence to HIV antiretroviral therapy in resource-poor settings. Such measures are essential to understand the unique barriers to adherence as access to HIV antiretroviral therapy expands. 30-day vi...

Hugen, P.W.H.; Langebeek, N.; Burger, D.M.; Zomer, B.; van Leusen, R.; Schuurman, R.; Koopmans, P.P.; Hekster, Y.A., 2002: Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. Background: Adherence to protease inhibitor-containing antiretroviral therapy is crucial, but difficult to measure. Objective: To compare and combine various methods of measuring adherence to the strict protease inhibitor-containing regimens. Meth...

Weiser, S.D.; Guzman, D.; Riley, E.D.; Clark, R.; Bangsberg, D.R., 2004: Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. Although evidence suggests that antiretroviral (ARV) regimens containing nonnucleoside reverse transcriptase inhibitors (NNRTIs) are superior to single-protease inhibitor (PI)-based regimens at suppressing viral load, it is unclear how much of the...